Wang et al. and Remdesivir: did Wang's LANCET publication May 2020 below blow Remdesivir out of the water as ineffective and deadly yet Fauci & NIH that day made Remdesiver standard of care? Yes!

Wang's trial should have ensured Remdesivir was DOA, but NIH & Fauci disregarded this study that was released SAME day, 'remdesivir was not associated with statistically significant clinical benefit'

SOURCE:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext

‘Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87–1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95–2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.

Interpretation

In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.’